Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities.

3区 医学 Q2 Medicine Current topics in microbiology and immunology Pub Date : 2024-08-11 DOI:10.1007/82_2024_268
Daniele Focosi
{"title":"Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities.","authors":"Daniele Focosi","doi":"10.1007/82_2024_268","DOIUrl":null,"url":null,"abstract":"<p><p>Monoclonal antibodies targeting the Spike protein of SARS-CoV-2 have been widely deployed in the ongoing COVID-19 pandemic. I review here the impact of those therapeutics in the early pandemic, ranging from structural classification to outcomes in clinical trials to in vitro and in vivo evidence of basal and treatment-emergent immune escape. Unfortunately, the Omicron variant of concern has completely reset all achievements so far in mAb therapy for COVID-19. Despite the intrinsic limitations of this strategy, future developments such as respiratory delivery of further engineered mAb cocktails could lead to improved outcomes.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in microbiology and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/82_2024_268","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Monoclonal antibodies targeting the Spike protein of SARS-CoV-2 have been widely deployed in the ongoing COVID-19 pandemic. I review here the impact of those therapeutics in the early pandemic, ranging from structural classification to outcomes in clinical trials to in vitro and in vivo evidence of basal and treatment-emergent immune escape. Unfortunately, the Omicron variant of concern has completely reset all achievements so far in mAb therapy for COVID-19. Despite the intrinsic limitations of this strategy, future developments such as respiratory delivery of further engineered mAb cocktails could lead to improved outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对 SARS-CoV-2 的单克隆抗体疗法:前景与现实。
针对 SARS-CoV-2 Spike 蛋白的单克隆抗体已被广泛应用于正在进行的 COVID-19 大流行中。我在此回顾了这些疗法在早期大流行中的影响,从结构分类到临床试验结果,再到体外和体内基础免疫逃逸和治疗引起的免疫逃逸的证据。不幸的是,令人担忧的奥米克龙变体完全重置了迄今为止针对 COVID-19 的 mAb 疗法所取得的所有成就。尽管这种策略存在固有的局限性,但未来的发展,如通过呼吸道输送更多的工程化 mAb 鸡尾酒,可能会带来更好的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
26
审稿时长
>12 weeks
期刊介绍: The review series Current Topics in Microbiology and Immunology provides a synthesis of the latest research findings in the areas of molecular immunology, bacteriology and virology. Each timely volume contains a wealth of information on the featured subject. This review series is designed to provide access to up-to-date, often previously unpublished information.
期刊最新文献
A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19. Alterations of the AKT Pathway in Sporadic Human Tumors, Inherited Susceptibility to Cancer, and Overgrowth Syndromes. Evidence for the Efficacy of COVID-19 Convalescent Plasma. HemoClear: A Practical and Cost-Effective Alternative to Conventional Convalescent Plasma Retrieval Methods. Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1